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Abstract The vasomotor effects of
ergotamine and dihydroergotamine
(DHE) on the middle cerebral
artery (MCA) of rats were studied
using the pressurised arteriography
method and in vitro myographs.
MCAs from Sprague–Dawley rats
were mounted on two glass
micropipettes using the arterio-
graph, pressurised to 85 mmHg
and luminally perfused. All vessels
used attained spontaneous contrac-
tile tone (34.9±1.8% of resting
tone) and responded to luminal
adenosine triphosphate (ATP) with
dilatation (24.1±4.0%), which
showed functioning endothelium.
Luminally added ergotamine or
DHE induced maximal contrac-
tions of 16.8+8% and 22.4±0.9%,
respectively, compared to the rest-
ing diameter, with a pEC50 of
8.7±0.1 for ergotamine and
9.0±0.1 for DHE. Abluminal appli-
cation of ergotamine and DHE also
caused concentration-dependent
contractions of the perfused MCA
by 21.4±2.1% and 23.1±7.0%,
respectively, with pEC50 values of
7.6±0.2 for ergotamine and
8.4±0.5 for DHE. The responses
were blocked by the 5-HT2A recep-
tor antagonist ketanserin (concen-
tration 10–12 to 10–5 M) and partial-
ly with the 5-HT1B receptor antago-
nist BRL-11557PM-B. The 5-HT1D
receptor antagonist SB-224289-A
had no significant effect. Using a
myograph technique, isolated ring
segments of the MCA with intact
endothelium were mounted on two
metal wires. Neither agonist
caused relaxation of resting ves-
sels, however, they both responded
by weak contractile responses
(26±3% of submaximal contractile
capacity relative to 60 mM potassi-
um). The contractions were typi-
cally slow in on and off set (about
30–60 min). The long duration of
ergots should be investigated fur-
ther in an attempt to design drugs
with less recurrence.
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Ergotamine and dihydroergotamine (DHE) are agents
that have a broad spectrum of effects at amine receptors
[1], including at the 5-HT1B/1D receptors, and have for
decades been used as acute anti-migraine drugs [2, 3].
They have the ability to constrict human cranial arteries
both in vitro and in vivo [3]. The constriction of intracra-
nial arteries (cerebral and middle meningeal arteries] is
considered an important target of anti-migraine therapy
[3], but inhibition of the release of calcitonin gene-related
84
peptide (CGRP) from sensory nerves is considered a
potential therapeutic target [4]. The vasoactive effects of
the ergotamines and triptans in intracranial arteries corre-
late to the presence of 5-HT1B/1D receptors in smooth mus-
cle cells in man [8]. The 5-HT2A receptor is expressed in
extracranial and peripheral vessels [5]. We have shown
that in man it is mainly the human temporal artery that has
5-HT2 receptors [6] and this vessel is constricted by ergo-
tamine [3]. Endothelial as well as smooth muscle cells of
human intracranial vessels have been demonstrated to
possess 5-HT1B receptors using specific 5-HT1B/1D receptor
antibodies as well as analysis of receptor mRNA [7–11].
For many years the standard method for in vitro phar-
macological examination of vascular pharmacology has
been to hook up a vessel segment on two prongs, one
fixed and the other connected to a strain gauge for record-
ing of vasomotion, however, all components of the vessel
walls are in these studies exposed to the drugs under
examination or removal of the endothelium will involve
trauma to the vessel wall. An alternative method has been
developed, namely pressurised arteriography [12–14].
Apart from being more similar to the in vivo environment
of blood vessels, the method offers the possibility of com-
partmentalised study of vascular responses (luminal vs.
abluminal application).
The aim of the present study is to examine in detail the
vasomotor effects of ergotamine and DHE on isolated per-
fused middle cerebral artery (MCA) of rats, particularly
rats have often been used in migraine models [15–18].
The questions we address are: where do ergotamine and
DHE act, can they pass the endothelium, and do they have
similar pharmacodynamics? Here we reveal that the
smooth muscle cells of the rat MCA contain primarily 5-
HT2A receptors, and only a minor population of 5-HT1B




The Animal Protocol Review committee at the University of
Lund approved the experimental protocol.
Male Sprague–Dawley rats (250–300 g) were anaesthetised with
CO2 and decapitated (n=20). The brain was immediately
removed and placed in cold (4°C) buffer solution of the follow-
ing composition (mM); NaCl 119, NaHCO3 15, KCl 4.6, MgCl2
1.2, NaH2PO4 1.2, CaCl2 1.5 and glucose 5.5. With the aid of a
dissecting microscope, MCA segments were carefully harvested
beginning at the circle of Willis and extending 5–8 mm distally.
Pressurised arteriograph
A section of the MCA (1–2 mm in length) was mounted in a pres-
surised arteriograph (Living Systems, Burlington, VT) as previ-
ously described [12, 13]. Micropipettes were inserted into both
ends of the MCA and secured with 11-0 nylon ties. The MCA was
superfused with the described buffer solution (37°C) equilibrated
with a gas mixture consisting of 5% CO2/95% O2, resulting in a
pH of 7.4. Via the glass micropipettes the MCA segment was per-
fused at a transmural pressure that was maintained at 85 mmHg
by raising reservoirs connected to the micropipettes to the appro-
priate height above the MCA. Luminal perfusion was adjusted to
100 µL/min by setting the two reservoirs at different heights.
These pressure/flow characteristics are considered to approxi-
mate the in vivo situation well. Pressure transducers on either side
of the MCA provided direct measurement of perfusion pressure
across the MCA. The vessel was magnified 600-fold using a
microscope coupled to a digital camera (Axis, Lund, Sweden)
connected to a PC. The program Mary (Nihil KB, Lund, Sweden)
saved the pictures at intervals of one second during the experi-
ment as well as measuring the diameter of the vessels.
Any MCA that did not develop spontaneous tone of at least
20% compared to the initial diameter within 1 h was excluded
from the experiment (approximately 15% of the total no. of ves-
sels mounted). The presence of a functional endothelium was
tested by luminal administration of adenosine triphosphate (ATP)
(10–5 M). A dilatation of at least 10% of the resting diameter was
considered indicative of a functional endothelium. Experimental
protocols were not initiated until the MCA diameter was stable
over a 15-min period. To test the vascular response to stimulation
of endothelial 5-HT receptors, ergotamine and DHE were added
to the luminal perfusate in the concentration range 10–12 to 10–6
M. In separate experiments the agonists were added abluminally
in the same concentration range to study the effect of adminis-
tration route and avoiding interaction with the endothelium.
To characterise the responses to luminal or abluminal stimu-
lation, ergotamine or DHE were used either alone or in the pres-
ence of antagonists for the 5-HT1B (BRL-1557PM-B), 5-HT1D
(SB-224289) or 5-HT2A receptor blockade with ketanserin.
Inhibitors were added both to the abluminal bath or the luminal
perfusate 20 min before commencing application of ergotamine
Table 1 The maximum relaxant responses and the pEC50 values of









or DHE, and were present during the experiments. Sumatriptan
(10–10 M to 10–4 M) was added luminally and abluminally.
Tissue bath experiments
Using the same buffer as described above, MCA segments (1
mm in length) were mounted on two metal wires (Myograph,
DMT, Aarhus, Denmark), one of which was connected to a force
displacement device. The experiments were continuously
recorded using PowerLab (ADInstruments, Oxford, UK) and the
software program Chart (ADInstruments, Oxford, UK), as previ-
ously described. The segments were tensioned to 2 mN and
allowed to rest at this tone for 1 h before commencing the exper-
iments [19]. To test for viability the segments were exposed to a
60 mM K+ buffer solution obtained by partial exchange of Na+
with K+ in the aforementioned buffer. The tension obtained here-
by was also used as reference for tissue contractile capacity.
Presence of a functional endothelium was tested through pre-
contraction with U46619 (a thromboxane A2 receptor agonist)
and subsequent relaxation with acetylcholine 10–5 M. A dilatation
of over 70% of the precontracted value was considered indica-
tive of a functional endothelium. The contractile response to
ergotamine or DHE was studied through cumulative application
in semilogarithmic steps, ending at 10–6 M. In additional experi-
ments vessel rings from rat MCA were suspended and concen-
trations of 10–6 and 10–5 M were studied. When maximum effect
was reached the bath was flushed repeatedly until baseline ten-
sion was reached and the time to maximum and time needed for
washing out the effect was noted. 
Statistical analysis
Data are expressed as mean values±SEM. For experiments per-
formed on the pressurised arteriograph, changes in measured
diameters of the vessel segments are expressed as a percentage
of the resting diameter. For vessel bath experiments, contraction
is expressed as a percentage of the contraction obtained expos-
ing the vessel to 60 mM K+, and dilatation as a percentage of the
tension obtained through precontraction. n refers to the number
of blood vessels tested in each experiment. Emax denotes the max-
imum response elicited by an agonist whereas pEC50 denotes the
negative logarithm of the concentration needed to elicit half the
maximum response. Sigmoidal curve fitting was done using the
computer program GraphPad Prism (GraphPad Software, San
Diego, CA, USA). Based on the principal equation for a sig-
moidal curve, the program makes iterated computations to
derive a best fit based upon the actual experimental values.
All concentrations expressed indicate the final concentration in
the luminal or abluminal compartments of the pressurised arteri-
ograph as well as in the vessel baths.
Statistical analysis was performed using Student’s t-test consid-
ering p values below 0.05 statistically significant.
Drugs used
ATP, acetylcholine, ergotamine, DHE, sumatriptan, ketanserin
and U466169 were obtained from Sigma (USA). BRL-
11557PM-B and SB-224289-A were generously provided by
Smithkline Beecham Pharmaceuticals, UK.
Stock solutions of the drugs were made following manufac-
turers’ instruction and stored frozen in small aliquots until use.
For experiments, drugs were diluted in the described buffer solu-
tion immediately before use. All chemicals were obtained from




The mean baseline diameter of the blood vessels exam-
ined was 187.3±4.6 µm after initial pressurisation and
121.4±3.6 µm after development of spontaneous tone
(n=20, p<0.001). The spontaneous myogenic tone (i.e.
contraction) developed was 34.9±1.8% of the initial ves-
sel diameter. ATP (10–5 M) applied luminally produced
relaxation of the myogenic tone by 24.1±4.0% (p<0.001).
Of the agonists applied luminally, only sumatriptan (n=7,
Emax 10±2%) induced relaxation of the MCA, with a pEC50
of 8.1±0.5 (n=7). Thus, ergotamine and DHE did not pro-
duce any significant relaxant effect upon luminal applica-
tion. The functional response to sumatriptan was indepen-
dent of administration route. Thus, abluminal application
also gave rise to relaxation with an Emax of 11±3% and a
pEC50 of 8.9±0.5. This was not statistically different from
the values obtained applying the drug luminally (p>0.05).
In separate tests this relaxant response has been charac-
terised and shown to occur via an endothelial mechanism
that involves 5-HT1B receptors and endothelial relaxing
factors [20].
Luminal and abluminal application of ergotamine or
DHE caused concentration-dependent contractions of the
perfused MCA (Fig. 1). The responses to abluminal appli-
cation of ergotamine were 21.4±2.1% while the luminal
application resulted in a response of 16.8±0.8%, and the
effects had pEC50 values of 7.6±0.2 and 8.7±0.1, respec-
tively (Fig. 1). The responses to DHE were similar,
23.1±7.0% (abluminal) vs. 22.4+0.9% (luminal) and a
similar pEC50 of 8.4±0.5 (abluminal) and 9.0±0.1 (Fig. 1).
The contractions elicited by ergotamine were mediated
through the 5-HT2A receptor as shown by the effect of
ketanserin, which significantly (p<0.05) reduced the Emax
from 21.4±2.1% (n=5) to 4.7±0.2% (n=4) (Fig. 2). For
DHE the results were similar (n=3; data not shown). Pre-
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baseline after 75 min after repeated washing. The effects
of DHE were slightly quicker but qualitatively similar.
The time to maximum contractile was 25–32 min with a
return to baseline 13–48 min after initiating the washing.
This illustrates the long on and off effects (Fig. 4).
Discussion
The present findings on the perfused MCA of the rat
demonstrate for the first time the direct contractile effects
of ergotamine while triptans act via an endothelial mech-
anism. The intraluminal or abluminal administration of
ergotamine and DHE consistently produce contraction
without any difference in magnitude abluminally and
luminally. The relaxation elicited by sumatriptan was
mediated through 5-HT1B receptors on the endothelial cells
(shown by the inhibitory action of GR 55562) and this
involves the release of nitric oxide (dilatation was inhibit-
ed by L-NOARG) [20]. The observation agrees with
immunocytochemical studies, which have shown that
there are endothelial 5-HT1B receptors both in rat [21] and
in man [8]. It was notable that it is only in man that there
is a rich supply of 5-HT1B receptors in the medial layer [8].
The contractile effects of ergotamine and DHE were
mainly mediated via 5-HT2A receptors as the specific 5-
HT2A receptor antagonist ketanserin acted as a powerful
antagonist. The 5-HT1B blocker BRL-15572PM-B in part
abolished the contractions while the 5-HT1D antagonist
SB-224289-A had no effect. This agrees well with a phar-
treating the vessel segments with the 5-HT1B antagonist
BRL-119557PM-B (n=5) in part blocked the contractile
responses (Fig. 3). The 5-HT1D antagonist SB-224289-A
had no effect (data not shown).
Tissue bath studies
The absolute contractile response of the MCA segments to
60 mM K+ was 3.0±0.2 mN. Contractile studies of ring
segments of rat MCA using single-dose application of
ergotamine or DHE (10–6 M) gave rise to contractile
responses of up to 66±13% vs. 13±5%, respectively, as
compared to the K+ response (set as 100%). The maxi-
mum effect of ergotamine was slowly developing and
reached maximum at about 20 min and had returned to
Fig. 1 Concentration–contraction curves for luminally and ablumi-
nally administered (a) ergotamine (n=7) and (b) dihydroergota-





















































Fig. 2 The effect of the selective 5-HT2A receptor antagonist
ketanserin on the contractile response of rat MCA to abluminally
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macological study of the rat basilar artery showing pow-
erful blockade by ketanserin of 5-HT-induced contractions
[22]. A 5-HT1 agonist 5-carboxytryptamine had, however,
a weak contractive effect which could be blocked by a 5-
HT1B/1D antagonist, suggestive of a minor population of 5-
HT1B receptors in the rat basilar artery [22]. The effects of
ergotamine on the isolated aorta have been studied exten-
sively [23]. Ergotamine constricted the isolated rat aorta
by acting on the 5-HT2A receptor while DHE did not con-
tract the rat aorta but acted as an insurmountable 5-HT2A
receptor antagonist [23]. In the present study both ergota-
mine and DHE acted as constrictors of the rat MCA pri-
marily via 5-HT2A receptors. The constrictive effect of
ergotamine on human basilar arteries has also been found
to be mediated by 5-HT receptors [24]. The vasoconstric-
tion induced by ergotamine and DHE in the external
carotid bed in dogs is mediated by 5-HT1B receptors and
alpha2A/2C-adrenoceptors [25–27]. In the present study the
vasoconstrictor effect was mediated by 5-HT2A receptors.
This illustrates that a vasoconstrictor may act on different
receptors depending on what part of the vascular tree and
species that is examined.
Ergotamine and DHE caused constriction of isolated
bovine middle cerebral arteries with a pEC50 of 8.0 [28].
Similarly, the pEC50 of ergotamine and DHE for the rat
MCA were 7.6–8.7 and 8.4–9.0, respectively, depending
on route of administration. Ergotamine and DHE are thus
potent vasoconstrictors that can selectively constrict the
cranial bed [3], a possible reason for their efficacy in
migraine. The two ergot alkaloids caused equally strong
vasoconstriction when administered luminally and ablu-
minally, indicating that they can cross the blood–brain
barrier [29], however, the pEC50 was slightly lower for the
abluminal administration.
Whereas the effect of ergotamine on blood flow is
short-lasting [30], the present study has demonstrated a
slow onset and a longer-lasting effect on isolated MCA,
lasting up to 45 min despite repeated flushing of the tissue
bath. Similarly, the constrictor effect of ergotamine could
not be washed out in human coronary arteries [31]. This is
in agreement with the long duration of constrictor effect
of ergotamine that can be seen both in man and in experi-
mental studies. Thus, a single parenteral dose of ergota-
mine caused a gradually developing constriction of leg
arteries lasting 30 h [30, 32]. In isolated veins the con-
strictor effect of DHE is slowly developing and persists
despite repeated washings of the in vitro bath [33]. The
slow onset and long duration of action of ergotamine is
compatible with a slow dissociation from the receptor
[30]. In contrast the effect of the new anti-migraine drugs,
the triptans, occurs immediately and is quickly washed
out. In rat sumatriptan dilates the MCA and basilar arter-















































Fig. 4 Example of contractile response of rat MCA to first the
administration of a high dose of potassium, followed by wash-out
and the administration of ergotamine which resulted in a fairly
strong contraction which levelled out at about 50% of maximum
and persisted for the duration of study










Fig. 3 The effect of the selective 5-HT1B antagonist BRL-
11557PM-B on contractile response of rat MCA to abluminally
administered (a) ergotamine (n=5) and (b) DHE (n=5). Values are
given as mean±SEM
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distribution difference in 5-HT receptor subtypes. The
anti-migraine effects of sumatriptan, ergotamine and DHE
have been compared in 5 randomised clinical trials; in
each case the triptan has a quicker onset of action than the
ergot alkaloids but at the same time a higher risk of
relapse of migraine headache [3]. Clinically speaking, the
triptans thus have one advantage over ergot alkaloids,
quicker onset of effect (a feature highly valued by
patients), but at the same time the high frequency of recur-
rence is a major problem often leading to repeated admin-
istrations of these drugs.
The ideal drug for treating a migraine attack would
thus combine two features: the quick onset of a triptan and
the long duration of effect of an ergot alkaloid. To design
such a drug basic insight into the reason for the long dura-
tion of effect of the ergot alkaloids is needed. For the
moment it is not possible to single this out from the dis-
advantage, the slow onset of effect. The effect of ergota-
mine and DHE differs markedly to the data we obtained
with triptans; they consistently induced relaxation via an
endothelial mechanism [20]. Obviously the dilatation of
rat MCA is dependent on the presence of an intact
endothelium as evidenced by the dependency on NO. As
sumatriptan is a specific agonist at the 5-HT1B/1D receptors
and an immunohistological study on human cerebral arter-
ies has shown 5-HT1B/1D receptors on the endothelium [8],
it is therefore reasonable to assume that endothelial 5-
HT1B/1D receptors are present in the rat endothelial cells. In
fact we have recently verified this using selective 5-HT1B
antibodies and confocal microscopy [21]. It is important
to note that, as rat intracranial arteries have a minor pop-
ulation of contractile 5-HT1B receptors in their medial
smooth muscle cells, it is not a good species to examine
the direct vasomotor effects of triptans. In conclusion, the
present study, using the pressurised arteriograph, shows
that ergotamine and DHE are potent constrictors of the rat
MCA by acting at the 5-HT2A receptor whereas sumatrip-
tan acts as a vasodilator via a 5-HT1B receptor. The effect
of ergotamine is of long duration probably due to slow
dissociation from the receptor.
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